阿贝西利驱动急性髓系白血病干细胞的治疗性分化
研究从2040种美国食品药品监督管理局批准药物中筛选发现CDK4/6抑制剂阿贝西利具有抗白血病活性,可在体外抑制白血病干细胞增殖并促进其分化,在临床前动物模型(含患者来源异种移植)中减轻白血病负荷并改善生存,与维奈克拉联用有协同抗白血病效应。
要点
- 阿贝西利在体外显著抑制白血病干细胞增殖并促进其分化。
- 阿贝西利在临床前动物模型(含患者来源异种移植)中诱导分化、损害自我更新、减少白血病负荷并改善生存。
- 阿贝西利与维奈克拉联用协同增强抗白血病效应,显著减少白血病干细胞富集群体。
核心结论
- 阿贝西利通过抑制CDK4/6及CDK9、降低p-Ser2 RNA聚合酶II羧基端结构域、Myc、Bcl-2和Mcl-1蛋白水平发挥抗急性髓系白血病作用。
- 这些数据为临床评估阿贝西利诱导白血病干细胞分化、治疗高度侵袭性急性髓系白血病及其他晚期血液恶性肿瘤提供了有力依据。
研究设计与样本
- 从美国食品药品监督管理局批准药物库中对2040种小分子进行筛选,以寻找克服急性髓系白血病分化阻滞的药物。
- 研究在体外及多种临床前动物模型(包括患者来源异种移植)中评价阿贝西利的抗白血病活性。
主要发现
- 阿贝西利在体外显著抑制白血病干细胞增殖并促进其分化。
- 阿贝西利在多种临床前动物模型(包括患者来源异种移植)中有效诱导分化并损害白血病干细胞自我更新,从而减少白血病细胞负荷并改善生存。
- 阿贝西利与Bcl-2抑制剂维奈克拉联用强烈增强抗肿瘤效应,导致白血病干细胞富集群体显著减少并产生协同抗白血病效应。
- 靶点筛选显示,除CDK4/6外,阿贝西利还结合并抑制CDK9,从而降低整体p-Ser2 RNA聚合酶II羧基端结构域、Myc、Bcl-2和Mcl-1的蛋白水平。
临床怎么用
- 原文结论认为这些数据为临床评估阿贝西利诱导白血病干细胞分化、治疗高度侵袭性急性髓系白血病及其他晚期血液恶性肿瘤提供了有力依据。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Self-renewal and differentiation arrest are two features of leukaemia stem cells (LSCs) responsible for the high relapse rate of acute myeloid leukaemia (AML). To screen drugs to overcome differentiation blockade for AML, we conducted screening of 2040 small molecules from a library of United States Food and Drug Administration-approved drugs and found that the cyclin-dependent kinase (CDK)4/6 inhibitor, abemaciclib, exerts high anti-leukaemic activity. Abemaciclib significantly suppressed proliferation and promoted the differentiation of LSCs in vitro. Abemaciclib also efficiently induced differentiation and impaired self-renewal of LSCs, thus reducing the leukaemic cell burden and improving survival in various preclinical animal models, including patient-derived xenografts. Importantly, abemaciclib strongly enhanced anti-tumour effects in combination with venetoclax, a B-cell lymphoma 2 (Bcl-2) inhibitor. This treatment combination led to a marked decrease in LSC-enriched populations and resulted in a synergistic anti-leukaemic effect. Target screening revealed that in addition to CDK4/6, abemaciclib bound to and inhibited CDK9, consequently attenuating the protein levels of global p-Ser2 RNA Polymerase II (Pol II) carboxy terminal domain (CTD), Myc, Bcl-2, and myeloid cell leukaemia-1 (Mcl-1), which was important for the anti-AML effect of abemaciclib. Collectively, these data provide a strong rationale for the clinical evaluation of abemaciclib to induce LSC differentiation and treat highly aggressive AML as well as other advanced haematological malignancies.
引用
- Xie X, Zhang W, Zhou X, et al. Abemaciclib drives the therapeutic differentiation of acute myeloid leukaemia stem cells. Br J Haematol. 2023. PMID: 36916190. doi:10.1111/bjh.18735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。